Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Streamlined, single-step non-viral CRISPR-Cas9 knockout strategy enhances gene editing efficiency in primary human chondrocyte populations

Fig. 3

TrueCut™ Cas9 v2 and sgRNA provided by Synthego lead to high HPRT editing efficiency. Editing efficiency of the HPRT locus was calculated upon Cas9-RNP delivery testing while comparing A three different Cas9 manufacturers, B the gRNA synthesized as either a cr:tracrRNA complex or sgRNA at various Cas9:gRNA ratios and C two distinct sgRNA providers, testing multiple Cas9:sgRNA ratios. Data are represented as mean ± standard deviation of 3 technical replicates from one donor (n = 3). Statistical significance was determined using one-way ANOVA with a Tukey’s multiple comparisons correction (** p < 0.01, and **** p < 0.0001)

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us